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ABSTRACT
Objective: To characterize the brain-infiltrating immune cell repertoire in Rasmussen encephalitis
(RE) with special focus on the subsets, clonality, and their cytokine profile.
Methods: The immune cell infiltrate of freshly isolated brain tissue from RE was phenotypically
and functionally characterized using immunohistology, flow cytometry, and T-cell receptor
(TCR) deep sequencing. Identification of clonally expanded T-cell clones (TCCs) was achieved
by combining flow cytometry sorting of CD41 and CD81 T cells and high-throughput TCR Vb-
chain sequencing. The most abundant brain-infiltrating TCCs were isolated and functionally
characterized.
Results: We found that CD41, CD81, and also gd T cells infiltrate the brain tissue in RE. Further
analysis surprisingly revealed that not only brain-infiltrating CD81 but also CD41 T cells are
clonally expanded in RE. All 3 subsets exhibited a Tc1/Th1 phenotype characterized by the pro-
duction of interferon (IFN)-g and TNF. Broad cytokine profiling at the clonal level showed strong
production of IFN-g and TNF and also secretion of interleukin (IL)-5, IL-13, and granzyme B, both
in CD41 and CD81 T cells.
Conclusions: CD81 T cells were until now considered the central players in the immunopatho-
genesis of RE. Our study adds to previous findings and highlights that CD41 TCCs and gd T cells
that secrete IFN-g and TNF are also involved. These findings underline the complexity of T-cell
immunity in RE and suggest a specific role for CD41 T cells in orchestrating the CD81 T-cell
effector immune response. Neurol Neuroimmunol Neuroinflamm 2018;5:e419; doi: 10.1212/
NXI.0000000000000419
GLOSSARY
IFN 5 interferon; IgG 5 immunoglobulin G; IL 5 interleukin; PHA 5 phytohemagglutinin; PMA 5 phorbol myristate acetate;
RE 5 Rasmussen encephalitis; TCC 5 T-cell clone; TCR 5 T-cell receptor; TCRBV 5 TCR b-chain variable.
Rasmussen encephalitis (RE) is a rare neurologic disorder mainly affecting children and causing
drug-resistant epilepsia partialis continua, intellectual decline, and neurologic deficits in parallel
with progressive hemispheric atrophy that, if untreated, will reach the final stage of the disease
with fixed severe neurologic symptoms.1 Efforts to characterize the pathogenesis and identify the
etiology of RE started already with the description of the disease by Rasmussen et al. in 1958.2
Both viral agents and antibody-mediated immune responses have been suspected or reported to
be involved in the pathophysiology of RE with, however, inconsistent results.3–6
The most robust evidence comes from recent research, which showed that RE-affected brain
tissue is characterized by clonally expanded CD81 T-cell infiltrates in the brain tissue, suggest-
ing a specific immunologic reaction to either exogenous or endogenous antigens.7–11 This notion
is supported by several small-size treatment studies with immunosuppressive/modulatory agents,
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which have in part shown promising results.12–16
Given that the most effective treatment remains
hemispherectomy/hemispherotomy with a sig-
nificant risk of functional deterioration, there is
a great need for better treatment options
directed against pathophysiologic aspects and/
or a potential cause of the disease.4
In this direction, we here studied the types
of immune cells infiltrating the brain in RE
using histopathology and ex vivo characteriza-
tion of isolated cells by flow cytometry. We
further investigated the presence of T-cell
clonal (TCC) expansions, generated and char-
acterized for the first time the most frequent
TCCs from the brain of a patient with RE,
and assessed their functional phenotype.
METHODS Patients. Case 1. A 4-year-old boy developed
progressive focal neurologic deficits and seizures. He was diag-
nosed with bilateral RE based on the clinical symptoms, radio-
logic findings (figure 1), and histopathologic analysis from brain
biopsies derived from both hemispheres. Cerebrospinal fluid
(CSF) studies revealed normal glucose and albumin quotient,
normal immunoglobulin G (IgG) index, no oligoclonal bands
and was negative for neurotropic viruses. The CSF was also tested
10 months later and was normal except for the presence of oli-
goclonal bands. The boy underwent left vertical parasagittal
hemispherotomy 1 and a half year later. Part of the resected brain
tissue was obtained for research analyses. Serum was tested and
was negative for paraneoplastic antibodies, namely antibodies
against NMDA receptor, AMPA, GABA (B), mGluR1, mGluR5,
LGI1, and Caspr2. The CSF was also tested and was negative for
antibodies against Hu, Ri, Yo, amphiphysin, CV2 (CRMP5), Ta/
Ma2, Ma1, SOX1 and GAD, LGI1, Caspr2, and NMDA
receptor (for further details, see online case description, appendix
e-1, http://links.lww.com/NXI/A11).
Case 2. A 36-year-old man underwent MRI showing findings
consistent with RE: hyperintense signal in the left cortical and
subcortical area with cortical atrophy and enlargement of the
lateral ventricle. A brain biopsy was consistent with RE and
included in the study.
Case 3. A female patient with RE underwent a partial resec-
tion of the right hemisphere at the age of 7 to treat status epilep-
ticus. Because of drug-resistant epileptic activity, the patient
underwent functional hemispherotomy at the age of 25. The
brain biopsy of the latter operation was included in this study and
was consistent with RE. The brain biopsy from the first operation
was not available.
Standard protocol approvals, registrations, and patient
consents. The project was approved by the Cantonal Ethics Com-
mittee Zurich (no. 33-2015), informed consent was obtained
accordingly from the parents of the 4-year-old boy, and approval
was received for the retrospective analyses of cases 2 and 3.
Immunohistochemistry. Formalin-fixed, paraffin-embedded
brain tissue sections of diagnostic brain biopsies (5-mm thick-
ness) were stained on a Leica Bond III–automated im-
munostaining platform (Leica Biosystems) with the appropriate
antibodies (table e-1, http://links.lww.com/NXI/A9) in 1%
bovine serum albumin. Tissue sections were analyzed using
a Nikon Eclipse 80i light microscope equipped with an Olympus
UC30 camera.
Isolation of brain-infiltrating mononuclear cells. This and
all subsequent methods were performed from CNS tissue that was
obtained and processed immediately after surgery from RE case 1.
The brain biopsy was cut into small pieces and incubated
with media containing 1 mg/mL collagenase A (Roche, Basel,
Switzerland) and 0.1 mg/mL DNAse I (Roche) at 37°C for
60 minutes. Brain-infiltrating cells were isolated by Percoll den-
sity gradient centrifugation (GE Healthcare, Buckinghamshire,
United Kingdom). The cells were characterized directly by flow
cytometry, expanded with phytohemagglutinin (PHA)-L (Sigma-
Aldrich, St. Louis, MO), or cryopreserved until further use.
Flow cytometry. For the direct phenotypic analysis of the
mononuclear brain infiltrate, Fc-binding blocking with human
IgG and staining with Live/Dead Aqua (Invitrogen, Waltham,
MA) was performed, followed by staining with the appropriate
antibodies (table e-1, http://links.lww.com/NXI/A9). Measure-
ments were performed on an LSR II flow cytometer (BD,
Franklin Lakes, NJ), and data were analyzed with FlowJo
(Ashland, OR).
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1
MRI (fluid-attenuated inversion recovery, FLAIR) in February 2013 (A), in September 2013 (B), and after left vertical para-
sagittal hemispherotomy in October 2013 (C). The arrows in B show subcortical regions with white matter FLAIR signal
abnormality. Note also the progressive atrophy of the brain and the left temporal lobe in particular.
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Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases
(A) Perivascular cuffing (hematoxylin and eosin [H&E]), prominent astrogliosis (GFAP), strong microglial activation
(HLA-DR staining), T-cell infiltrates (CD31NeuN), and absence of B cells (CD20) are shown. (B) Representative
images showing CD81 T cells infiltrating the tissue, some of them in proximity or direct contact to neurons
(CD81NeuN) and also, in all 3 cases, CD41 T cells as well as gd T cells (gd-TCR) infiltrating the brain parenchyma.
For CD81NeuN, CD4, and gd-TCR, a higher magnification of the small regions in squares is shown on the top right
inset of each image. Scale bar 5 100 mm except for GFAP and HLA-DR 5 200 mm. GFAP 5 glial fibrillary acidic
protein; HLA-DR 5 human leukocyte antigen; RE 5 Rasmussen encephalitis; TCR 5 T-cell receptor.
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High-throughput T-cell receptor sequencing. DNA was
isolated using the AllPrep DNA/RNA Mini Kit (Qiagen,
Limburg, Netherlands), and high-throughput sequencing for
Vb T-cell receptor (TCR) was performed at Adaptive Bio-
technologies (Seattle, WA) using the immunoSEQ platform.17–19
Expansion of brain-infiltrating mononuclear cells and
generation of TCCs. Brain-infiltrating mononuclear cells were
expanded as bulk populations by seeding into 96-well plates
2,000 cells/well together with 1.5 3 105 allogeneic irradiated
(3,000 radians) peripheral blood mononuclear cells, 1 mg/mL of
PHA and human interleukin-2 (IL-2; supernatant kindly pro-
vided by Federica Sallusto, PhD, Bellinzona, Switzerland) in
IMDMmedium supplemented with 2mM L-glutamine, 100 U/mL
penicillin/streptomycin, 50 mg/mL gentamicin, and 5% human
serum. IL-2 was added every 3–4 days, and at day 14, cells were
pooled and cryopreserved. TCCs were generated by fluorescence
activated cell sorting (FACS) (FACSAria III; BD) of specific T-
cell populations stained with anti-CD4, anti-CD8, and appro-
priate anti-TCR Vb antibodies (Beckman Coulter, Brea, CA) and
subsequently cloned by limiting dilution (0.3 cells/well) in 96-
well plates. TCCs were then expanded using the above-described
protocol and rechecked for purity by sequencing of the specific
TCR Vb chain (Microsynth, Balgach, Switzerland) and flow
cytometry.
Cytokine expression profiling of expanded brain-
infiltrating T cells. Brain-infiltrating mononuclear cells were
analyzed for cytokine profiling after 1 expansion using intracellu-
lar cytokine staining on stimulation with 50 ng/mL phorbol myr-
istate acetate (PMA; Sigma-Aldrich) and 1 mg/mL ionomycin
(Sigma-Aldrich) in the presence of GolgiPlug (BD). After 5
hours, T cells were stained with Live/Dead Aqua, fixed and
permeabilized with the Cytofix/Cytoperm Kit (BD), and stained
with the appropriate antibodies (table e-1, http://links.lww.com/
NXI/A9). Unstimulated cells served as controls. Measurements
were performed on an LSRFortessa flow cytometer (BD), and
data were analyzed with FlowJo.
Cytokine expression profiling of TCCs. TCCs were stimu-
lated with PMA and anti-CD3 (OKT3 antibody; Janssen-Ortho,
Toronto, Canada) for 24 hours. Cytokine secretion of individual
TCCs was measured in supernatants using a Th1/Th2/Th17
Cytokine Multi-Analyte ELISArray Kit (Qiagen) and a granzyme
B ELISA kit (Mabtech, Nacka Strand, Sweden). Data were
analyzed using GraphPad Prism (La Jolla, CA).
RESULTS All 3 subtypes, CD41, CD81, and gd, are
forming the T-cell infiltrate in RE. We first performed
immunohistochemical analyses to investigate the
similarities between the 3 RE cases. All 3 cases dis-
played prominent astrogliosis, strong microglial acti-
vation, T-cell infiltrates, and essential absence of B
cells (figure 2A). Further characterization of the T-
cell infiltrate confirmed the presence of CD81 T
cells, some of them in direct contact to neurons in
accordance with what has been described before.8
The histopathologic findings were thus consistent
with RE in all 3 cases. We observed also in all 3
cases the presence of CD41 T cells both in the peri-
vascular compartment and in the parenchyma as
well as infiltrating gd T cells (figure 2B). Apart from
the T-cell staining, the gd-TCR antibody also
displayed a regional staining of glial cells (data not
shown).
To confirm these histopathologic findings and
quantitatively assess and perform a more detailed
analysis of the brain-infiltrating cells, we used brain
tissue resected at hemispherotomy surgery from
case 1. Figure 3A shows the methodological strategy
of dissecting the tissue into 4 segments (seg1–seg4)
for the various analyses.
Flow cytometric analysis of leukocytes (CD451)
obtained from fresh brain tissue (seg4) revealed a pre-
dominant T-cell infiltrate (CD31, 93.1%) consisting
of CD41 (30.9%) and CD81 (46.6%) T cells. Both
subpopulations displayed effector memory pheno-
types. B cells (CD191) comprised only 1.8% of the
cell population, confirming the immunohistochemical
analysis. We also found 33.1% of the infiltrating
T cells to be gd T cells with 65.4% being Vd11, while
only a minority expressed Vd21. The remaining frac-
tion of gd T cells was Vd12 Vd22 (most probably
Vd31 T cells). Both Vd21 and Vd12 Vd22 T cells
were partially also CD81 (figure 3B). Of note, gd
T cells are a small subset of T cells as compared to
ab T cells, have a distinct TCR on the surface, and
constitute only 1%–5% of total blood lymphocytes
being mainly Vd21. The presence of monocytes
(CD141, 1%) and natural killer cells (CD561,
2.1%) was sparse (data not shown). To further char-
acterize the brain T-cell infiltrate, CD81, CD41, and
gd1 T cells were in vitro PHA expanded (1 round).
Analysis of the cytokine profile of these expanded
brain-infiltrating T cells revealed that all 3 subpopu-
lations (CD81, CD41, and gd1 T cells) displayed
a similar profile expressing the proinflammatory cyto-
kines interferon (IFN)-g and TNF and in addition the
degranulation marker of cytotoxicity CD107a
(figure 3C). We thus found that all 3 subtypes,
CD41, CD81, and gd, are forming the T-cell infiltrate
in RE and express a proinflammatory (Th1-like) profile.
Both CD41 and CD81 T-cell brain infiltrates are clonally
expanded. We sequenced the TCR b-chain variable
(TCRBV genes) expressed by T cells infiltrating seg2
and seg4 of the RE brain tissue. This sequencing can
be used to trace clonal lineages and thus potentially
identify the same clonal lineages in seg2 and seg4.
Five hundred seventy-six unique productive se-
quences were identified in seg2. The complete list of
Vb-chain, J-chain, CDR3 sequences and frequencies
is given in table e-2, http://links.lww.com/NXI/A10.
The 13 most frequent TCCs are highlighted in a 3D
histogram (figure 3D) and summarized in figure e-1
(http://links.lww.com/NXI/A8). To discriminate
between CD41 and CD81 TCCs, we then sequenced
the TCRBV chain expressed by sorted CD41 and
CD81 T cells isolated from seg4 following 1 round of
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PHA expansion. Five hundred fifty-three and 291
unique productive sequences were identified in the
CD41 and in the CD81 brain-infiltrating T-cell
pool, respectively. The most frequent TCCs in seg2
that are present in the brain-infiltrating CD41 T-cell
pool and CD81 T-cell pool from seg4 are shown in
Figure 3 Methodological strategy, flow cytometric analysis, cytokine profile, and clonality of brain-infiltrating cells
(A) Methodological strategy of dissecting the brain tissue (dimensions: 2 3 6 3 1.5 cm) for various analyses: segment (seg) 1 was kept for further analyses.
Seg2 was taken for DNA extraction and subsequent high-throughput TCR sequencing. Seg3 was embedded in paraffin and used in immunohistochemical
studies. Seg4 was used for isolation of brain-infiltrating mononuclear cells with subsequent (1) phenotypic analyses by flow cytometry, (2) expansion with
phytohemagglutinin, FACS of CD41 and CD81 T cells, DNA extraction, and subsequent high-throughput TCR sequencing, and (3) T-cell cloning (TCC).
(B) Flow cytometry analysis (seg4) of the brain-infiltratingmononuclear cells. (C) Cytokine profile of brain-infiltrating T cells. (D) High-throughput TCR sequencing
(seg2) showing oligoclonal expansions of both CD41 and CD81 T-cell infiltrates. CM 5 central memory; EM 5 effector memory; TCR 5 T-cell receptor.
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red and blue, respectively (figure 3D and figure e-1,
http://links.lww.com/NXI/A8). Five of the 13 most
frequent TCCs in seg2 were not present in the
CD41 or CD81 compartment of the expanded
pools from seg4 (shown in black). The 2 most fre-
quent TCCs in seg2 representing 15.56% and 13.
04% of the T-cell infiltrate were both CD81. The
third most expanded TCC in seg2 representing 6.
81% of the T-cell infiltrate was a CD41 TCC. The
overall TCC match between seg2 and seg4 was 14.
5% for CD41 and 38.8% for CD81 TCCs, while
46.7% of the infiltrating T cells in seg2 were not
present in seg4. We thus found that both CD41 and
CD81 T-cell brain infiltrates are clonally expanded
in RE case 1.
Functional phenotype of brain-infiltrating clonally
expanded TCCs. We next generated 5 CD41 and 1
CD81 TCC from CD41 and CD81 sorted and pre-
viously PHA-expanded (1 round) T cells obtained
from RE brain tissue seg4. This was performed to
characterize the functional phenotype of the indi-
vidual TCCs found in RE case 1. The 5 CD41 TCCs
obtained were among the 6 most frequent TCCs in
the pool of sorted and expanded CD41 T cells from
seg4. The CD81 TCC was the most frequent one in
the CD81 T-cell pool (figure 4, A and B). Of interest,
2 of the CD41 TCCs were also present in seg2. Based
on our previous studies, a bias as a consequence of 1
round of PHA expansion is unlikely.20 We therefore
assume that partially overlapping T-cell repertoires
Figure 4 Cytokine expression profile of individual T-cell clones
(A) The frequencies of CD41 (red) or CD81 (blue) TCCs that were identified in seg4 are shown in a 3D histogram. Note the similar clonality of CD41 and CD81
T cells. TCCs that were generated by limiting dilution and analyzed for cytokine expression are numbered and shown in bold. (B) The Vb-chain, J-chain, and
CDR3 sequence of TCRs from the most frequent TCCs as well as the cytokine profile of the derived TCCs are shown. Cytokine production is illustrated with
a color gradient from pale to bolder that corresponds to lower and higher cytokine levels, respectively. (C) High levels of granzyme B secretion by both the
CD41 and CD81 TCCs on stimulation. n.p. 5 not present. IFN 5 interferon; IL 5 interleukin; TCC 5 T-cell clone; TCR 5 T-cell receptor.
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shape the infiltrate in physically separate areas of the
brain in this RE case. A search using the BLASTP
program of the nonredundant protein database (blast.
ncbi.nlm.nih.gov) indicated that none of the TCR
sequences found in seg2 and seg4 matched any
published sequence in the database.
We examined the functional phenotype of the 6
brain-infiltrating TCCs by analyzing their cytokine
profile (figure 4B). Among the CD41 TCCs, 2 TCCs
(TCC3 and TCC16) displayed a Th1 phenotype
releasing mainly Th1 cytokines, 2 TCCs (TCC14
and TCC15) had a Th1/2 multifunctional pheno-
type, and TCC18 released mainly Th2 cytokines.
The only CD81 TCC analyzed (TCC23) released
both Th1 and Th2 cytokines and hence exhibited
also a multifunctional phenotype (figure 4B). Both
the CD41 TCCs and the CD81 TCC produced
granzyme B on stimulation (figure 4C). We thus
observed both Th1 and Th1/2 multifunctional cyto-
toxic phenotypes of the individual TCCs.
DISCUSSION In this study, we report that besides
CD81 T cells, both ab CD41 TCC and gd T cells
infiltrate the brain in RE. Further analyses using
FACS of CD41 and CD81 T cells and TCR Vb-
chain high-throughput sequencing from 2 different
segments of brain tissue identified that not only the
brain-infiltrating CD81 but also the CD41 T cells are
clonally expanded. Prior evidence has shown that T
cell–mediated inflammation in RE is dominated by
CD81 TCCs, while an involvement of CD41 TCCs
has not been considered.7,11,21 In a seminal previous
study, the investigators matched the TCR Vb
between blood and brain T cells in 5 patients and
found only CD81 T cells to be present in the RE
brain.7 For this reason, our finding that a large frac-
tion of the TCCs that were present in both brain
segments, and in particular the third and sixth most
frequent TCCs, were CD41, is surprising. The reason
for the discrepancy between the previous study and
ours is unclear but could be explained by methodo-
logical differences. Although, the previous study
included more patients, identification of brain TCCs
as being CD41 or CD81 T cells was performed by
matching them to peripheral blood CD41 or CD81
TCCs. On the other hand, the setup and methods
used in our study with direct sorting and sequencing
from 2 different segments of the brain lesion allowed
phenotyping the T-cell subpopulations directly from
the brain. In support of our findings, histopathologic
studies have also reported the presence of CD41
T cells in the RE brain.22–25 Our study, which
documents not only the presence but also clonal
expansion of CD41 T cells, indicates that CD41
T cells are likely involved in the disease process of RE
and driven by a specific antigen. Given that this
finding is derived from a bilateral RE case, further
studies are needed to investigate whether this is also
true for more typical RE cases in which only 1 hemi-
sphere is affected.
In addition to the oligoclonal expansion of CD41
and CD81 T cells, the presence of gd T cells suggests
further complexity of the immunopathogenesis. We
found that a major fraction (one-third) of the brain-
infiltrating gd T cells belong to the non-Vd21 sub-
type. Because blood gd T cells are mainly Vd21, our
finding indicates a specific infiltration rather than
bystander recruitment into the brain. Almost half of
the gd T cells were positive for CD8, which suggests
that prior histopathologic assessments of RE tissue
with anti-CD8 antibodies might have overestimated
the contribution of CD81 ab T cells because at least
a significant proportion of the CD81 T cells belong
to the gd T-cell compartment. gd T cells constitute
1%–5% of total blood lymphocytes and approxi-
mately 50% of the lymphocytes in skin and mucosal
tissues. They mediate defense mechanisms against
bacteria, viruses, and protozoa and play a role in can-
cer, wound healing, and autoimmune diseases.26
Regarding CNS autoimmunity, previous studies have
shown that gd T cells are present in MS lesions, are
oligoclonally expanded, and probably can react
against heat-shock proteins.27–29 It is important that
a recent study has also reported the presence of gd
(CD42CD82Vd11) T cells with a restricted T-cell
repertoire in RE.30 Thus, because gd T cells are impli-
cated in RE and both in viral/infectious and autoim-
mune diseases of the CNS, they should be included in
future efforts to uncover the etiology of the disease.
A previous study comparing brain tissue from pa-
tients with RE and cortical dysplasia analyzed the cyto-
kine profile in RE using reverse transcription PCR and
showed evidence for a Th1/Tc1 response.24 We here
report the cytokine profile of the most frequent, CNS-
infiltrating T-cell populations and individual TCCs in
the brain. Individual CD41 TCCs displayed a Th1
phenotype with IFN-g and TNF secretion or a more
complex multifunctional phenotype with additional
secretion of IL-5 and IL-13. When investigating all 3
subpopulations of brain-infiltrating cells, namely
CD41, CD81, and gd T cells, the majority of the cells
expressed IFN-g and TNF but not IL-17.
In its most common form, RE affects only 1 hemi-
sphere, but rare cases exist, in which the disease starts
at earlier age, is more severe, and affects both hemi-
spheres.31 In case 1 with bilateral hemispheric
involvement, the clinical course of the disease, involv-
ing the typical RE prodromal period, the intractable
focal seizures followed by the acute stage until sur-
gery, the MRI findings and evolution, the absence of
antibodies involved in autoimmune encephalopa-
thies, the histopathology being in accordance with
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the Bien diagnostic criteria and compatible with what
usually is seen in typical unilateral RE cases, as eval-
uated by 2 independent neuropathologists, the classic
finding of T cells being in contact to neurons, and,
finally, the response to surgical treatment strongly
support that this is one of the very rare cases of bilat-
eral RE.32 The presence of brain-infiltrating gd T cells
in all 3 cases also strongly suggests that bilateral and
unilateral cases have a similar pathogenesis.
Taken together, our data fit well with previous
knowledge and provide new insights regarding the
immunopathogenesis of RE. Previous studies in
RE have demonstrated that CD81 T cells cluster
around neurons that express phosphorylated STAT1
and show loss of synapses. In a model of viral
encephalitis, this process of synapse elimination de-
pended on IFN-g production by CD81 T cells,33
and we here provide evidence that brain-derived
CD81 T cells indeed produce IFN-g in RE. The
CD81 TCC in addition expresses granzyme B, indi-
cating that CD81 T cells can induce death of astro-
cytes and neurons that express MHC class I through
direct cell-cell contact and release of granzyme
B.8,9,21 The strong expression of MHC class II and
the presence of CD41 TCCs suggest that CD41 T
cells react to specific brain antigens and secrete
proinflammatory cytokines that play a role in
orchestrating and/or supporting the CD81 T-cell
response. Although the helper function of CD41
T cells may be their most important role, CD41
TCCs produce IFN-g and granzyme B at levels sim-
ilar or even higher than CD81 TCCs. Hence, CD41
T cells may also act as cytotoxic effectors, i.e., by the
above-mentioned IFN-g–mediated elimination of
synapses, by inducing glial apoptosis and by
enhancing tissue damage via granzyme B.33–36
Finally, the identification of brain-infiltrating gd T
cells as part of the inflammatory process in RE im-
plicates a third T-cell subtype.
Overall, we find that the T-cell infiltrate in RE is
considerably more complex than previously thought.
While our data do not allow to discern which of the
T-cell subtypes initiates the inflammatory process,
their common cytokine patterns indicate that they
jointly participate in the pathogenesis of RE. It will
be important now to identify the target antigens of
both CD41 and CD81 TCCs and clarify if these
are self- or foreign antigens and if molecular mimicry
is involved. Future studies about the possible antigens
causing or driving the disease should investigate all 3
T-cell populations, CD81 and CD41 TCCs, and gd
T cells. To this end, we have expanded for the first
time the most prominent CD41 and CD81 TCCs,
which can be used as important tools in unbiased
approaches to identify possible antigens involved in
the etiology and/or pathogenesis of RE.
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